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ABSTRACT
We present a case of a 56-year-old man with a history of episcleritis (left) and cluster headache (left) who had a penetrating trauma of 
the left eye leading to amaurosis 1 month previously. Since then, he developed multiple cranial neuropathy of the right side (V, VII, VIII, 
IX, X, XI and XII cranial pairs). Magnetic resonance imaging (MRI) revealed an infiltrative lesion of the base of the skull which extended to 
the retropharyngeal and jugular space, which progressed to multiple leptomeningeal masses extending to the clivus, despite aggressive 
immunosuppression. Rebiopsy of 1 meningeal mass supported the diagnosis of neurosarcoidosis. The patient finally responded to high-dose 
prolonged infliximab therapy, with complete remission.
LEARNING POINTS
• Neurosarcoidosis can present as multiple cranial neuropathy, with extensive nerve involvement depending on the brain and meningeal 
lesions.
• Large leptomeningeal pseudotumoural granulomatous masses should be promptly biopsied and lead to aggressive immunosuppressive 
treatment.
• Immunosuppressant weaning should be carried out cautiously to avoid rebound worsening.
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CASE DESCRIPTION
We present a case of a 56-year-old man, a cattle worker and former smoker (15 packs/year), with well-controlled arterial hypertension and 
diabetes mellitus. He had a 2-year history of multiple episodes of episcleritis (left eye) and left hemicranial cluster headache, for which he 
had been treated with systemic and topical corticosteroids and azathioprine (discontinued due to toxic hepatitis). One month before his 
referral to us, he had a left eye penetrating trauma (from a cow’s horn) leading to amaurosis.
When we met him, the patient had right side otomastoiditis and hypoacusia, right peripheral facial palsy with ptosis, no right palate elevation, 
palsy and atrophy of the tongue, total dysphagia necessitating a nasogastric tube for feeding and an inability to elevate the right shoulder 
against resistance. Brain magnetic resonance imaging (MRI) found diffuse soft tissue thickening with imprecise limits extending to the clivus 
(Fig. 1A), with intense contrast enhancement extending to the retropharyngeal space and jugular region (Fig. 1B) along with inflammatory 
signs of the right mastoid and middle ear (Fig. 1C).
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Figure 1. (A) Diffuse soft tissue thickening with imprecise limits extending to the clivus; (B) intense diffuse contrast enhancement extending to the retropharyngeal space and 
jugular region; (C) inflammatory signs of the mastoid and middle ear secondary to Eustachian tube obstruction by soft tissue thickening
Complete blood cell count showed mild anaemia, an elevated sedimentation rate (52 mm/first hour), no evidence of kidney dysfunction 
or abnormalities of urinary sediment, a normal liver panel, normal serum and urinary calcium and normal angiotensin-converting enzyme 
(ACE). Cerebrospinal fluid analysis showed normal glucose and proteins, ACE 13 U/l, evidence of intrathecal production of IgG (9 oligoclonal 
bands of IgG with no correspondence in serum analysis), microbiologic analysis was sterile and testing for anti-neuronal antibodies was 
negative.
Serologies were unremarkable (HIV-1/2, HBV, HCV, EBV, CMV, HSV-1 and -2, varicella-zoster and Brucella). VDRL was also negative. 
Immunological assessment showed normal IgA, IgG, IgG4, IgM, C3 and C4. ANAs tested positive in a titre of 1/80, nucleolar pattern, 
and testing for ANCA, anti-SS-A, anti-SS-B, anti-centromere, anti-Scl-70, anti-PM/Scl, anti-dsDNA and anti-Smith was negative. Neck 
and cervical computed tomography (CT) angiography as well as thoraco-abdomino-pelvic CT did not have relevant findings. 18F-FDG 
positron emission tomography showed metabolic activity in the retropharyngeal space, mediastinal and hilar lymph nodes. The biopsy of 
retropharyngeal tissue showed chronic inflammatory infiltrate with lymphohistiocytic granulomas and no signs of lymphoma, neoplasm or 
vascular involvement, and negative microbiological results (bacterial, fungal and mycobacterial studies) were obtained. 
Treatment was needed, and although no definitive diagnosis could be established, we assumed sarcoidosis-like granulomatous disease, with 
mainly neurological involvement with multiple cranial neuropathy, possible leptomeningitis and IgG intrathecal synthesis.
The patient started treatment with systemic prednisolone (1 mg/kg/day) and intravenous (IV) cyclophosphamide 1 g monthly for 6 months 
(Table 1) with resolution of the deficits.
Table 1. Treatment (doses and dates)
Despite maintenance therapy with oral methotrexate (17.5 mg/week) for 1 year, symptoms including severe headache and total dysphagia 
subsided after prednisolone withdrawal below 20 mg/day. IV cyclophosphamide was reintroduced but by the fourth monthly cycle, no 
response was noted. Infliximab was started at a dose of 3.5 mg/kg/cycle every 4 weeks with no response in the first 3 months and a new 
differential diagnosis work-up was made. 
MRI showed a leptomeningeal enhancement with extension to the occipital region and soft tissue mass through the lateral orbital cavities 
(Fig. 2) and a right suboccipital craniectomy was performed, for a dura mater biopsy: more than 20 elastic viscous masses (Fig. 3A) were 
found lining the internal skull base and 1 was removed. Histological examination confirmed granulomatous lesions with lymphoplasmacytic 
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infiltrates, multinucleated giant cells and non-caseous necrosis, with no vasculitis and no acid-alcohol resistant bacilli (Fig. 3B–E), and there 
was a negative microbiologic work-up (bacteria, mycobacteria and fungi).
Figure 2. MRI with 
leptomeningeal 
enhancement with 
extension to the occipital 
region
Infliximab dosage was increased to 5 mg/kg/cycle every 4 weeks and the clinical response was excellent, allowing the progressive reduction 
of prednisolone dosage and the total resolution of symptoms. 
The patient experienced transitory symptomatic worsening when we tried to change infliximab frequency to every 6 weeks, and this 
resolved again with the 4-week interval for 1 year. The corticosteroid has been slowly weaned to 2.5 mg/day currently, and the patient is in 
complete clinical and MRI remission. He is now on infliximab every 5 weeks, for 6 months.
DISCUSSION
Sarcoidosis has neurological involvement in approximately 5 to 15% of cases. Neurosarcoidosis may manifest as a wide variety of non-
specific symptoms, such as headache, dizziness, fatigue and fever, but cranial neuropathy is the most common neurologic manifestation of 
sarcoidosis and multiple cranial neuropathy with predominant unilateral involvement is often seen. This may be explained by the predilection 
for basilar meninges involvement with granulomatous infiltration, observed in almost 40% of neurological cases [1]. 
Brain tissue vulnerability and the low threshold for procedure-induced damage makes histopathological characterization of neurosarcoidosis 
less well known compared with other organ involvement, and in patients with neurological single organ manifestation, the diagnosis may 
be harder to confirm. In our patient, extensive investigation led to the exclusion of the majority of other differential diagnoses, mainly 
infectious or neoplastic aetiologies that could be life-threatening. A multidisciplinary approach encompassing otolaryngology, vascular 
surgery, neurology, neurosurgery, neuroradiology and internal medicine was crucial to guide this process. It seems to be in no doubt at the 
moment that the patient has neurosarcoidosis, with no other clinical involvement besides the central nervous system, but with 18F-FDG 
Figure 3. (A) Macroscopic image of 
the leptomeningeal mass (diameter: 
approximately 2 cm) surgically 
removed for histologic examination. 
(B) Granulomatous lesion with 
lymphoplasmacytic and histiocytic 
infiltrates; some PMN; non-caseous 
necrosis; (C) multinucleated giant 
cells (arrows); (D) predominance of 
histiocytes (CD68); (E) predominance 
of lymphocytes (CD3)
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PET evidence of thoracic lymph node inflammation. In fact, in only 1% of cases, neurosarcoidosis can be isolated and limited to the nervous 
system [2]. Although cranial neuropathies are frequent, we did not find other reports with so many cranial nerves involved (V, VII, VIII, IX, 
X, XI and XII). The trigeminal nerve (V) and vestibulocochlear nerve (VIII) are extremely rarely affected[3]. The presence of intrathecal IgG 
synthesis has also been reported in the literature[4].
Neurosarcoidosis treatment choices are based on expert opinion papers and small case series or case reports. The intensity of treatment 
depends on the severity of the manifestations: high steroids are the basis, but relapses are common and many patients will need additional 
induction and maintenance immunosuppressive therapy. Cyclophosphamide is traditionally used as a wide-spectrum immunosuppressant. 
Infliximab inhibits high TNF-α expression sarcoidosis granulomas with a good neurological penetration and has been used for refractory 
cases. A multi-institutional retrospective study with 66 patients led to recommendations supporting the use of TNF-α inhibitors in 
neurosarcoidosis, based on a favourable imaging and clinical response in three-quarters of patients treated with infliximab, although there 
were high relapse rates after discontinuation, consistent with other reports[5].
In our patient’s evolution, several steps can be discussed: was the initial cyclophosphamide 6-month treatment too short? If so, why was 
there no response on the second 4-month trial? Should we have chosen infliximab in the first place? It is clearer now that the dose of 
infliximab should have been 5 mg/kg/cycle every 4 weeks from the beginning. Since the patient is in remission for 2 years with a very low 
dose of corticosteroid, the main questions now are: how to wean it? And when to stop?
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